/
Respiratory
Obstructive Sleep Apnea
38
Pipeline Programs↗
125
Active Trials↗
51
Companies Involved↗
Obstructive Sleep Apnea is a moderately active landscape with 38 programs across 51 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Innovent Biologics (Suzhou) Co. Ltd., Gan & Lee Pharmaceuticals.. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical23
Phase 11
Phase 24
Phase 310
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
28 of 32 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 84% of 38 pipeline programs.
Analysis
Trial Status
287
clinical trials
Completed122 · 43%
Recruiting65 · 23%
Not yet recruiting41 · 14%
Withdrawn15 · 5%
Active, not recruiting13 · 5%
Unknown status12 · 4%
Other19 · 7%
Clinical Trials
Trial Activity
287 trials
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults (ESSENTIAL) Study
Recruiting·CCalifornia Pacific Medical Center Research Institute·Preclinical·NCT05988385·200 enrolled
Comparative Effectiveness of Positive Airway Pressure Therapy, Dental Device, and Atomoxetine-Oxybutynin for Sleep Apnea: the ADAPT-OSA Study
Recruiting·—·Approved·NCT07679282·2,400 enrolled
Application of the PLATO Questionnaire in Oral Appliance Therapy for Obstructive Sleep Apnea
Recruiting·—·N/A·NCT07789834·20 enrolled
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)